Chimerix, Inc.
Durham, North Carolina, United States
Joshua Allen, PhD, Senior Vice President of R&D at Oncoceutics, discovered ONC201 and co-invented the imipridone class of compounds. He directed the preclinical studies that identified ONC201 as an anti-cancer agent, defined its preclinical profile, elucidated its novel mechanism of action, and extended its pharmacophore into a new class of therapies. Dr. Allen received his Ph.D. in Biochemistry and Molecular Biophysics from the University of Pennsylvania and completed a post-doctoral fellowship in pharmacology at the Penn State Cancer Institute. Dr. Allen has authored several research publications and awarded grants for preclinical and clinical development of novel therapies and biomarkers. Several awards have recognized his entrepreneurial research and development efforts in different areas of oncology, including recognition on the 2016 Forbes 30 under 30 list. Dr. Allen joined Oncoceutics in 2012.
